Casimersen New Drug Application Submitted for DMD
Sarepta Therapeutics has completed the submission of the casimersen NDA for the treatment of DMD in patients who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
Treatments
Missed Opportunities for Secondary ASCVD Prevention After Stroke
Uptake of guideline-directed preventive therapies is lower for patients with stroke and peripheral artery disease compared with those with coronary artery disease.
Greater Proportion of RMS Patients Achieve NEDA-3 With Ofatumumab vs Teriflunomide
Treatment with ofatumumab was associated with a greater proportion of patients with relapsing forms of multiple sclerosis achieving no evidence of disease activity, compared with those who received teriflunomide.
Methods for Injecting OnabotulinumtoxinA for Migraine Prevention Vary Between Clinicians
Researchers explored alterations in PREEMPT protocol and the explanations for them using an anonymous questionnaire to headache clinicians.
FDA Grants Fast Track Status to Arimoclomol for ALS
The FDA has granted Fast Track designation to arimoclomol (Orphazyme A/S) for the treatment of amyotrophic lateral sclerosis.
Sublingual Apomorphine Hydrochloride Approved for Off Episodes in Parkinson Disease
This sublingual film formulation of apomorphine was designed for use as a fast-acting, on-demand treatment for all types of motor off episodes.
Unapproved Cannabidiol, Curcumin Injectables Marketed for Multiple Disorders Recalled
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
Open Label Extension Trial Depicts Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis
Long-term treatment with inotersen is effective for polyneuropathy secondary to hATTR amyloidosis with a promising long-term safety profile.
A Review of Pharmacologic Treatment Options for Painful Diabetic Neuropathy
The management of painful diabetic peripheral neuropathy requires the use of effective agents that also may aid in improving sleep and mood.
Satralizumab Can Delay and Reduce Neuromyelitis Optica Spectrum Disorder Relapse Rate
Satralizumab monotherapy may reduce the risk for neuromyelitis optics spectrum disorder relapse, and has a favorable safety profile.
-
Loading...
-
Loading...
Next post in General Neurology
